Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Cordlife Group ( (SG:P8A) ) is now available.
Cordlife Group Limited has received confirmation from Singapore’s Ministry of Health that its cord blood banking service licence has been renewed for one year from 14 January 2026 to 13 January 2027, while its human tissue banking service licence has been renewed for two years until 13 January 2028. The cord blood banking licence renewal comes with additional conditions that are substantially the same as those imposed earlier when regulators modified the licence and ordered the company to halt the collection, testing, processing and storage of new cord blood units, underscoring ongoing regulatory scrutiny and signalling that Cordlife’s ability to fully resume normal operations in cord blood banking remains constrained even as its core licences are kept in force.
The most recent analyst rating on (SG:P8A) stock is a Sell with a S$0.13 price target. To see the full list of analyst forecasts on Cordlife Group stock, see the SG:P8A Stock Forecast page.
More about Cordlife Group
Cordlife Group Limited is a Singapore-based company operating in the healthcare sector, specialising in cord blood banking and human tissue banking services. The company focuses on the collection, testing, processing and storage of cord blood units and other human tissues, serving families who wish to preserve these biological materials for potential future medical use.
Average Trading Volume: 37,920
Technical Sentiment Signal: Strong Sell
Current Market Cap: S$33.19M
For detailed information about P8A stock, go to TipRanks’ Stock Analysis page.